Supernus (SUPN) Form 4: Director Disposes 1,412 Shares Under Trading Plan
Rhea-AI Filing Summary
Charles W. Newhall III, a director of Supernus Pharmaceuticals, Inc. (SUPN), reported the sale of 1,412 shares of the company’s common stock on 08/22/2025. The sales were made pursuant to a Rule 10b5-1 trading plan adopted March 3, 2025, and the price reported is a weighted average of $45, with individual sale prices ranging from $45.00 to $45.01. After the reported disposition, the reporting person beneficially owned 134,232 shares, held directly.
The filing is signed on behalf of the reporting person by an attorney-in-fact, Timothy C. Dec, dated 08/26/2025. The reporting person offers to provide details of the number of shares sold at each separate price within the disclosed range upon request.
Positive
- Transaction executed under a 10b5-1 trading plan, indicating it was pre-authorized
- Weighted average sale price disclosed ($45) and range ($45.00–$45.01) with offer to provide per-price details on request
- Post-transaction beneficial ownership disclosed (134,232 shares), providing transparency
Negative
- Disposition of 1,412 shares reduced the reporting person’s direct holdings
- No information on total outstanding shares or percentage ownership is provided in this filing, limiting context
Insights
TL;DR: Routine insider sale under a 10b5-1 plan; modest reduction in direct holdings does not by itself indicate a material change to ownership.
The report shows a small block disposal of 1,412 shares at an average price of $45 under a pre-established 10b5-1 plan adopted March 3, 2025. The filing discloses the post-transaction direct beneficial ownership of 134,232 shares. For investors, this is a transparent, rule-compliant insider sale; the size of the sale relative to total holdings reported here appears limited. No derivative transactions or additional material changes to ownership are reported.
TL;DR: Compliance-focused disclosure: the sale was executed under a documented 10b5-1 plan and properly reported on Form 4.
The filing explicitly states the transaction was made pursuant to a 10b5-1 trading plan and provides the weighted average price and the disclosed price range. Signature by an attorney-in-fact is included. From a governance perspective, the form meets disclosure requirements and offers additional transparency by offering to provide per-price sale breakdowns on request. No stock option exercises, grants, or other governance actions are included in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,412 | $45.00 | $64K |
Footnotes (1)
- Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.01, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
